Latest Breaking News On - Asset sale to cosette pharmaceuticals - Page 1 : vimarsana.com

Palatin s Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED).

United statesCarl spanaPalatin technologies incCosette pharmaceuticalsPrnewswire palatin technologies incVyleesi to cosette pharmaceuticalsMetabolic program obesityAsset sale to cosette pharmaceuticalsSexual health program male dysfunctionBremelanotide coSecurities exchangeMelanocortin receptorDry eye diseaseTopline data expectedUlcerative colitisInterim analysis expected